

AMENDED CLAIMS

**[Received by the International Bureau on 13 APR 2004 (13.04.04) ;
original claims 1 – 52, replaced by claims 1 – 21]**

1. A use of mannan-binding lectin (MBL) for the manufacture of a life saving medicament to treat or cure critically ill patients.
2. A use of mannan-binding lectin (MBL) for the manufacture of a life saving medicament to treat or cure critically ill patients at risk of death.
3. The use of MBL of claim 1, for the manufacture of a medicament to increase the survival rate in the intense care unit (ICU).
4. The use of MBL of claim 1, for the manufacture of a medicament to reduce the time that a critically ill patient stays, within the hospital, for example within the intense care unit
5. The use of MBL of claim 1, wherein the "condition" is post-surgical critical illness.
6. The use of MBL of claim 1, wherein the "condition" is post-traumatic critical illness.
7. The use of any of the claims 1 to 6, wherein the MBL polypeptide monomer is a mammalian MBL polypeptide monomer.
8. The use of the claims 1 to 6, wherein the mammalian MBL polypeptide monomer is a human MBL polypeptide monomer.
9. The use of the claims 1 to 6, wherein said oligomer is preferably selected from the group of oligomers consisting of trimers, tetramers, pentamers and/or hexamers.
10. The use of the claims 1 to 6, wherein the MBL comprises at least one mannan-binding lectin (MBL) polypeptide monomer, or at least one mannan-binding lectin (MBL) polypeptide oligomer comprising or at least one mannan-binding lectin (MBL) polypeptide monomer.
11. The use of the claims 1 to 6, wherein MBL comprises at least one mannan-binding lectin (MBL) polypeptide oligomer comprising at least one mannan-binding lectin (MBL) polypeptide monomer.
12. The use of the claims 1 to 11, wherein medicament is used in such way that the blood blood MBL level in the critical ill patient is kept above 250 ng/ml
13. The use of the claims 1 to 11, wherein medicament is used in such way that the blood blood MBL level in the critical ill patient is kept above 500 ng/ml
14. The use of the claims 1 to 11, wherein medicament is used in such way that the blood MBL level in the critical ill patient is kept above 1000 ng/ml

15. The use of the claims 1 to 11, wherein medicament is used in such way that the blood MBL level in the critical ill patient is kept between 1000 ng/ml and 2000 ng/ml
16. The use of claims 1 to 15, wherein the medicament is administered to the individual prior to another treatment at ICUs.
17. The use of claims 1 to 15, wherein the medicament is administered to the individual simultaneously, sequentially or separately with another treatment.
18. The use of claim 1 to 15, wherein the medicament is administered to the individual prior to, during and after said other treatment.
19. The use of any of claims 1 to 18, wherein the medicament is a booster of MBL polypeptide serum levels in an critically ill patient having MBL polypeptide serum levels below a predetermined minimum MBL polypeptide serum level.
20. Use of any of the claims 1 to 19, wherein the medicament is for the prevention of fatal outcome during intensive care treatment of an individual.
21. Method of using a MBL polypeptide composition for preventing death in a critical ill individual, the method comprising the steps of:
 - i) determining serum levels of MBL polypeptide in an individual,
 - ii) estimating the probability of the occurrence of intensive care complications in the individual, and optionally,
 - iii) administering a MBL polypeptide composition to an individual.